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Abstract
Background—The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate 
precisely associated cancer risks. Population-based family studies have provided evidence that at 
least some of these mutations are associated with breast cancer risk as high as those associated 
with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare 
variants in PALB2, CHEK2 and ATM via a multicentre case-control study.
Methods—We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, 
c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, 
and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 
cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 
542 cases and 23 491 controls) cancer risk, for each variant.
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Results—For European women, strong evidence of association with breast cancer risk was 
observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G>A 
OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10−8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, 
p=0.0012). We also found evidence of association with breast cancer risk for three variants in 
CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) 
and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was 
observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and 
CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of 
association with ovarian cancer was found for any of these variants.
Conclusions—This report adds to accumulating evidence that at least some variants in these 
genes are associated with an increased risk of breast cancer that is clinically important.
INTRODUCTION
The rapid introduction of massive parallel sequencing (MPS) into clinical genetics services 
is enabling the screening of multiple breast cancer susceptibility genes in one assay at 
reduced cost for women who are at increased risk of breast (and other) cancer. These gene 
panels now typically include the so-called ‘moderate-risk’ breast cancer susceptibility genes, 
including PALB2, CHEK2 and ATM.1–3 However, mutations in these genes are individually 
extremely rare and limited data are available with which to accurately estimate the risk of 
cancer associated with them.
Estimation of the age-specific cumulative risk (penetrance) of breast cancer associated with 
specific mutations in these three genes has been limited to those that have been observed 
more frequently, such as PALB2 c.1592delT (a Finnish founder mutation), PALB2 c.
3113G>A and ATM c.7271T>G. These mutations have been estimated to be associated with 
a 40% (95% CI 17% to 77%), 91% (95% CI 44% to 100%) and 52% (95% CI 28% to 80%) 
cumulative risk of breast cancer to the age of 70 years, respectively.4–7 These findings, based 
on segregation analyses in families of population-based case series, indicate that at least 
some mutations in these ‘moderate-risk’ genes are associated with a breast cancer risk 
comparable to that of the average pathogenic mutation in BRCA2: 45% (95% CI 31% to 
56%).8 However, such estimates are imprecise and, moreover, may be confounded by 
modifying genetic variants or other familial risk factors.
Case-control studies provide an alternative approach to estimating cancer risks associated 
with specific variants. This design can estimate the relative risk directly, without making 
assumptions about the modifying effects of other risk factors. However, because these 
variants are rare, such studies need to be extremely large to provide precise estimates.
The clearest evidence for association, and the most precise breast cancer risk estimates, for 
rare variants in PALB2, CHEK2 and ATM relate to protein truncating and splice-junction 
variants.910 However, studies based on mutation screening in case-control studies, combined 
with stratification of variants by their evolutionary likelihood suggest that at least some 
evolutionarily unlikely missense substitutions are associated with a similar risk to those 
conferred by truncating mutations.11–13 For example, Tavtigian et al12 estimated an OR of 
2.85 (95% CI 0.83 to 4.86) for evolutionarily unlikely missense substitutions in the 3′ third 
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of ATM, which is comparable to that for truncating variants. Specifically, ATM c.7271C>G 
has been associated with a more substantial breast cancer risk in several studies.713 Le 
Calvez-Kelm et al,11 estimated that the ORs associated with rare mutations in CHEK2 from 
similarly designed studies were 6.18 (95% CI 1.76 to 21.8) for rare protein-truncating and 
splice-junction variants and 8.75 (95% CI 1.06 to 72.2) for evolutionarily unlikely missense 
substitutions.11
It is plausible that monoallelic mutations in PALB2, CHEK2 and ATM could be associated 
with increased risk of cancers other than breast cancer, as has been observed for BRCA1 and 
BRCA2 and both ovarian and prostate cancers. 14–17 However, with the exception of 
pancreatic cancer in PALB2 carriers, there is little evidence to support or refute the existence 
of such associations, although a few individually striking pedigrees have been 
observed.4818–20
In this study we selected rare genetic variants on the basis that they had been observed in 
breast cancer candidate gene case-control screening projects involving PALB2, CHEK2 or 
ATM . These included three rare variants in PALB2: the protein truncating variants c.
1592delT (p.Leu531Cysfs)4 and c.3113 G>A (p.Trp1038*)6 and the missense variant c.
2816T>G, (p. Leu939Trp), six rare missense variants in CHEK2: c.349A>G (p.Arg117Gly) 
and c.1036C>T (p.Arg346Cys) predicted to be deleterious on the basis of evolutionary 
conservation,11 c.538C>T ( p.Arg180Cys), c.715G>A (p.Glu239Lys), c.1312G>T 
(p.Asp438Tyr) and c.1343T>G (p.Ile448Ser) and ATM c.7271T>G (p.Val2424Gly).7 We 
assessed the association of these variants with breast, ovarian and prostate risk by case-
control analyses in three large consortia participating in the Collaborative Oncological Gene-
environment Study.2122
METHODS
Participants
Participants were drawn from studies participating in three consortia as follows:
The Breast Cancer Association Consortium (BCAC), involving a total of 48 studies: 37 of 
women from populations with predominantly European ancestry (42 671 cases and 42 164 
controls), 9 of Asian women (5795 cases and 6624 controls) and 2 of African-American 
women (1046 cases and 932 controls). All cases had invasive breast cancer. The majority of 
studies were population-based or hospital-based case-control studies, but some studies of 
European women oversampled cases with a family history or with bilateral disease (see 
online supplementary table S1). Overall, 79% of BCAC cases with known Estrogen Recptor 
(ER) status (23% missing) are ER-positive. The proportion of cases selected by family 
history that are ER-positive is 78% (38% missing).
The Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the 
Genome (PRACTICAL) involving a total of 26 studies: 25 included men with European 
ancestry (22 301 cases and 22 320 controls) and 3 included African-American men (623 
cases and 569 controls). The majority of studies were population-based or hospital-based 
case-control studies (see online supplementary table S2).
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The Ovarian Cancer Association Consortium (OCAC), involving a total of 46 studies. Some 
studies were case-only and their data were combined with case-control studies from the 
same geographical region (leaving 36 study groupings). Of these groupings, 33 included 
women from populations with predominantly European ancestry (16 287 cases (14 542 with 
invasive disease) and 23 491 controls), 25 included Asian women (813 cases (720 with 
invasive disease) and 1574 controls), 17 included African-American women (186 cases (150 
with invasive disease) and 200 controls) and 29 included women of other ethnic origin (893 
cases (709 with invasive disease) and 864 controls). The majority of studies were 
population-based or hospital-based case-control studies (see online supplementary table S3).
Details regarding sample quality control have been published previously.2223 All study 
participants gave informed consent and all studies were approved by the corresponding local 
ethics committees (see online supplementary tables S1–S3).
Variant selection
We selected for genotyping 13 rare mutations that had been observed in population-based 
case-control mutation screening studies. These variants were PALB2 (c.1592delT, p. 
Leu531Cysfs;4510 c.2323C>T p.Gln775*;20 c.2816T>G, p. Leu939Trp;220 c.3113G>A, 
p.Trp1038*;2620 c.3116delA, p. Asn1039IIefs;2620 c.3549C>G, p.Tyr1183*2), CHEK2 (c.
349A>G, p.ArgR117Gly; c.538C>T, p.Arg180Cys; c.715G>A p.Glu239Lys; c.1036C>T, 
p.Arg346Cys; c.1312G>T, p.Asp438Tyr; c.1343T>G, p.Ile448Ser)11 and ATM (c.7271T>G, 
p.Val2424Gly)71324 see table 1. A DNA sample carrying each of these variants was included 
in a plate of control DNAs that was distributed to each genotyping centre to assist with 
quality control and genotype calling.
Genotyping
Three PALB2 variants c.2323C>T (p.Gln775*), c.3116delA (p.Asn1039IIefs) and c.
3549C>G (p.Tyr1183*) were unable to be designed for measurement on the custom Illumina 
iSelect genotyping array and were not considered further (table 1). Genotyping was 
conducted using a custom Illumina Infinium array (iCOGS) in four centres, as part of a 
multiconsortia collaboration as described previously.22 Genotypes were called using 
Illumina’s proprietary GenCall algorithm and then, for the data generated from the rare 
variant probes, manually confirmed with reference to the positive control sample. Two per 
cent of samples were provided in duplicate by all studies and 270 HapMap2 samples were 
genotyped in all four genotyping centres. Subjects with an overall call rate <95% were 
excluded. Plates with call rates <90% were excluded on a variant-by-variant basis. Cluster 
plots generated for all of the 10 rare variants were manually checked to confirm automated 
calls (see online supplementary figure S1).
Statistical methods
The association of each variant with breast, prostate and ovarian cancer risk was assessed 
using unconditional logistic regression to estimate ORs for carriers versus non-carriers, 
adjusting for study (categorical). p Values were determined by the likelihood ratio test 
comparing models with and without carrier status as a covariate. We also applied conditional 
logistic regression, defining risk sets by study, and found that this made no difference to the 
Southey et al. Page 4
J Med Genet. Author manuscript; available in PMC 2016 December 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
OR estimates, CIs or p values to two significant figures; since model convergence was a 
problem for this latter regression analysis, all subsequent analyses were based on 
unconditional logistic regression. For the main analyses of breast cancer risk in European 
women, we also included as covariates the first six principal components, together with a 
seventh component specific to one study (Leuven Multidisciplinary Breast Centre (LMBC)) 
for which there was substantial inflation not accounted for by the components derived from 
the analysis of all studies. Addition of further principal components did not reduce inflation 
further. Data from all breast cancer studies were included to assess statistical significance. 
Data from cases selected for inclusion based on personal or family history of breast cancer 
were excluded in order to obtain unbiased OR estimates for the general population of white 
European women (leaving 37 039 cases and 38 260 controls from 32 studies). Multiple 
testing was adjusted for using the Benjamini-Hochberg procedure to control the false 
discovery rate, with a significance threshold of 0.05.25 Reported p values are unadjusted 
unless otherwise stated. Reported CIs are all nominal. We included two race-specific 
principal components in each of the main breast cancer analyses of Asian and African-
American women. Similar analyses were conducted using the data from PRACTICAL and 
OCAC, consistent with those used previously.2326 All analyses were carried out using Stata: 
Release V.10 (StataCorp, 2008).
RESULTS
PALB2
In BCAC, PALB2 c.1592delT (Leu531Cysfs) was only observed in 35 cases and 6 controls, 
all from four studies from Sweden and Finland (Helsinki Breast Cancer Study (HEBCS), 
Kuopio Breast Cancer Project (KBCP), Oulu Breast Cancer Study (OBCS) and Karolinska 
Mammography Project for Risk Prediction Breast Cancer (pKARMA); see online 
supplementary table S1), giving strong evidence of association with breast cancer risk 
(p=7.1×10−5); the OR estimate was 4.52 (95% CI 1.90 to 10.8) based on all studies and 3.44 
(95% CI 1.39 to 8.52) based on unselected cases and controls (table 2). We also found 
evidence of heterogeneity by ER status (p=0.0023), the association being stronger for ER-
negative disease (OR 6.49 (95% CI 2.17 to 19.4) versus 2.24 (95% CI 1.05 to 7.24) for ER-
positive disease).
PALB2 c.3113G>A (p.Trp1038*) was identified in 44 cases and 8 controls from nine BCAC 
studies. Only one carrier of the variant was of non-European origin. Strong evidence of 
association with breast cancer risk was observed (p=6.9×10−8), with an estimated OR of 
5.93 (95% CI 2.77 to 12.7) based on all studies and 4.21 (95% CI 1.85 to 9.61) based on 
unselected cases and controls. There was no evidence of a differential association by ER 
status (p=0.15).
Based on unselected cases, the estimated OR associated with carrying either of these PALB2 
variants (c.1592delT or c.3113G>A) was 3.85 (95% CI 2.09 to 7.09).
PALB2 c.2816T>G (p.Leu939Trp) was identified in 150 cases and 145 controls and there 
was no evidence of association with risk of breast cancer. There was no evidence of 
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association with risk of prostate or ovarian cancer for any of the three PALB2 variants (see 
tables 3 and 4).
CHEK2
CHEK2 c.349A>G (p.Arg117Gly) was identified in 44 cases and 18 controls in studies 
participating in BCAC; all of these women were of European origin. We found evidence of 
association with breast cancer (p=0.003), with little change in the OR after excluding 
selected cases (OR 2.03 (95% CI 1.10 to 3.73)).
CHEK2 c.538C>T (p.Arg180Cys) was identified in 158 breast cancer cases and 142 controls 
in studies of white Europeans. Evidence of association with breast cancer risk (p=0.016) was 
observed, with an unbiased OR estimate of 1.34 (95% CI 1.06 to 1.70). A consistent OR 
estimate was observed for Asian women, based on 45 case and 45 control carriers (OR 1.16 
(95% CI 0.75 to 1.76)).
CHEK2 c.715G>A (p.Glu239Lys) mutations were identified in 15 cases and 9 controls, all 
European women participating in BCAC and no evidence of association with risk of breast 
cancer was observed (p=0.21).
CHEK2 c.1036C>T (p.Arg346Cys) was identified in nine cases from seven studies and two 
controls from two different studies in BCAC (neither control carrier was from a study that 
had case carriers), all of European origin. We found evidence of association with breast 
cancer risk (p=0.017) with reduced OR estimate of 3.39 (95% CI 0.68 to 16.9) after 
excluding selected cases.
None of the above four CHEK2 variants (CHEK2 c.349A>G (p.Arg117Gly); c.538C>T 
(p.Arg180Cys); c.715G>A (p. Glu239Lys) and c.1036C>T (p.Arg346Cys)) were found to be 
associated with an increased risk of prostate or ovarian cancer (tables 3 and 4). CHEK2 
variant c.1312G>T (p.Asp438Tyr) was not associated with risk of breast cancer for 
European women (p=0.91). Variant c.1343T>G (p.Ile448Ser) was not observed in any breast 
cancer cases of European or Asian origin. It was detected in 48 cases and 29 controls of 
African origin, giving weak evidence of association (OR 1.52 (95% CI 0.95 to 2.43, 
p=0.083)). CHEK2 c.1312G>T (p.Asp438Tyr) was identified in 23 cases and 11 controls 
from PRACTICAL, all European, providing evidence of association with prostate cancer 
risk (OR 2.21 (95% CI 1.06 to 4.63, p=0.030)). CHEK2 c.1343T>G (p. Ile448Ser) was 
observed in 35 cases and 11 controls, all African, participating in PRACTICAL and was also 
associated with an increased risk of prostate cancer (OR 3.03 (95% CI 1.53 to 6.03, 
p=0.00059)). There was no evidence that these CHEK2 variants were associated with risk of 
ovarian cancer (table 4).
ATM
ATM c.7271T>G (p.Val2424Gly) was identified in 12 cases and 1 control in studies 
participating in BCAC, all of European origin, giving evidence of association with breast 
cancer risk (p=0.0012). The OR estimate based on unselected studies was 11.0 (95% CI 1.42 
to 85.7). There was no evidence of association of this variant with prostate or ovarian cancer 
risk (see tables 3 and 4).
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DISCUSSION
The present report adds to an accumulating body of evidence that at least some rare variants 
in so-called ‘moderate-risk’ genes are associated with an increased risk of breast cancer that 
is of clinical relevance.
These findings are presented at a time when detailed information about variants in these 
genes is becoming more readily available via the translation of diagnostic genetic testing 
from Sanger sequencing-based testing platforms to MPS platforms that test panels of genes 
in single assays. 27–29 The vast majority of information about PALB2, CHEK2 and ATM, 
variants generated from these new testing platforms is not being used in clinical genetics 
services due to lack of reliable estimates of the cancer risk associated with individual 
variants, or groups of variants, in each gene. Previous analyses have been largely based on 
selected families, relying on data on the segregation of the variant. The present study is by 
far the largest to take a case-control approach. Consistent with previous reports,5–7911–13 
PALB2 c.3113G>A (p.Trp1038*), PALB2 c.1592delT (p.Leu531Cysfs) and ATM c.
7271T>G (p.Val2424Gly) were found to be associated with substantially increased risk of 
breast cancer all with associated relative risk estimates of 3.44 or greater.
The estimates for the two loss-of-function PALB2 variants (c.1592delT and c.3113G<A) 
were consistent with each other and with estimates based on segregation analysis. 569 We 
found no evidence of association with breast cancer for PALB2 c.2816T>G (p.Leu939Trp), 
with an upper 95% confidence limit excluding an OR >1.5 which is notable given the Align-
Grantham Variation Granthan Deviation (Align-GVGD) score and the observed impact on 
protein function.30
The estimate for ATM c.7271T>G (p.Val2424Gly) was also consistent with that found by 
segregation analysis.713 The substantial increased risk of breast cancer associated with AT M 
c.7271T>G (p.Val2424Gly) could be due to the reduction in kinase activity (with near-
normal protein levels) observed for ATM p.Val2424Gly,31 thus this variant is likely to be 
acting as a dominant negative mutation.32
In contrast, we found no evidence of an association with risk of prostate or ovarian cancer 
with any of these three variants: however, the confidence limits were wide; based on the 
upper 95% confidence limit we could exclude an OR of >1.4 for prostate cancer for the loss-
of-function PALB2 c.3113G>A and 1.9 for c.1592delT and c.3113G>A combined.
We analysed six rare missense variants in CHEK2. Two of these (CHEK2 c.349A>G 
(p.Arg117Gly; rs28909982) and c.1036C>T (p.Arg346Cys)) had evidence of a significant 
impact on the protein based on in silico prediction. We proposed these variants for inclusion 
in the iCOGS design as they had been identified in 3/1242 cases and 1/1089 controls and 
3/1242 cases and 0/1089 controls, respectively, in a population-based case-control mutation 
screening study of CHEK2.11 In that study, Le Calvez-Kelm et al, estimated an OR of 8.75 
(95% CI 1.06 to 72.2) for variants with an Align-GVGD score C65 (based on nine cases and 
one control). The current analysis provides confirmatory evidence of this association in a 
much larger sample (OR 2.18 (95% CI 1.23 to 3.85)) including 40 unselected case and 18 
control carriers. The evidence that CHEK2 is a breast cancer susceptibility gene is largely 
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based on studies of protein truncating variants, in particular CHEK2 1100delC.33 Reports of 
the association of the missense variant I157T, (C15) and breast cancer risk have been 
conflicting but a large meta-analysis involving 15 985 breast cancer cases and 18 609 
controls estimated a modest OR of 1.58 (95% CI 1.42 to 1.75).34 We also found evidence 
(p=0.015) of an association for c.538C>T (Align-GVGD C25); OR 1.34 (95% CI 1.06 to 
1.70), a risk comparable to I157T.
The p values reported above have not been adjusted for multiple testing. This was not 
considered appropriate for the associations with breast cancer risk of PALB2 c.1592delT, c.
3113G>A and ATM c.7271T>G because these associations had previously been reported; 
our aim was to more precisely estimate the associated relative risks. All three associations 
with breast cancer risk reported for CHEK2 variants remained statistically significant after 
adjusting for the other tests conducted in relation to breast cancer risk, but not after 
correcting for all tests for all cancers. Nevertheless, the findings for CHEK2 c.349A>G and 
c.1036C>T confirmed those reported previously, although collectively. The association 
observed with CHEK2 c.538C>T requires independent replication.
Do this approach and new data have an impact on clinical recommendations for women and 
families carrying these rare genetic variants? Although age-specific cumulate risks for 
cancer are more informative for genetic counselling and clinical management of carriers, our 
study provides information that is relevant to clinical recommendations. As discussed in 
Easton et al,35 a relative risk of 4 will place a woman in a ‘high-risk’ category (in the 
absence of any other risk factor) and a relative risk between 2 and 4 will place a woman in 
this category if other risk factors are present. Thus, several of the variants included in this 
report (PALB2 c.1592delT; c.3113G>A ATM c.7271T>G) would place the carrier in a high-
risk group, especially if other risk factors, such as a family history, are present. The high 
level of breast cancer risk associated with PALB2 c.1592delT and c.3113G>A reported here 
is consistent with the penetrance estimate reported for a group of loss-of-function mutations 
in PALB29 and has an advantage in terms of clinical utility that the estimates in this study 
have been made at a mutation-specific level. Therefore, this work provides important 
information for risk reduction recommendations (such as prophylactic mastectomy and 
potentially salpingo-oophorectomy) for carriers of these variants. However, further 
prospective research is required to characterise these risks and to understand the potential of 
other risk-reducing strategies such as salpingo-oophorectomy and chemoprevention.
The consistency of the relative risk estimates with those derived through family based 
studies supports the hypothesis that these variants combine multiplicatively with other 
genetic loci and familial risk factors; this information is critical for deriving comprehensive 
risk models. Even with very large sample sizes such as those studied here, however, it is still 
only possible to derive individual risk estimates for a limited set of variants, and even for 
these variants the estimates are still imprecise. This internationally collaborative approach 
also has limited capacity to improve risk estimates for rare variants that are only observed in 
specific populations. Inevitably, therefore, risk models will depend on combining data across 
multiple variants, using improved in silico predictions and potentially biochemical/
functional evidence to synthesise these estimates efficiently. It will also be necessary 
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develop counselling and patient management strategies that can accommodate a 
multifactorial approach to variant classification.
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Refer to Web version on PubMed Central for supplementary material.
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Table 3
Summary results from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in 
the Genome studies for white European men* (22 301 prostate cancer cases and 22 320 controls)
Variant
Frequency†
Controls
Frequency†
Cases OR (95% CI)
LRT
p Value
PALB2
  c.1592delT (p.Leu531Cysfs) 0.00018 0.00031 2.06 (0.59 to 7.11) 0.24
  c.2816T>G (p.Leu939Trp) 0.00354 0.00381 0.95 (0.69 to 1.29) 0.73
  c.3113G>A (p.Trp1038*) 0.00045 0.00027 0.49 (0.18 to 1.36) 0.16
CHEK2‡
  c.349A>G (p.Arg117Gly) 0.00063 0.00081 1.46 (0.71 to 3.02) 0.30
  c.538C>T (p.Arg180Cys) 0.00341 0.00296 1.02 (0.73 to 1.44) 0.90
  c.715G>A (p.Glu239Lys) 0.00018 0.00027 1.47 (0.41 to 5.35) 0.55
  c.1036C>T (p.Arg346Cys) 0.00018 0.00022 1.07 (0.28 to 4.07) 0.93
  c.1312G>T (p.Asp438Tyr) 0.00049 0.00103 2.21 (1.06 to 4.63) 0.03
  c.1343T>G (p.Ile448Ser) 0 0.00009 – –
  c.1343T>G (Africans§) 0.019 0.057 3.03 (1.53 to 6.03) 0.001
ATM
  c.7271T>G (p.Val2424Gly) 0.00004 0.00027 4.37 (0.52 to 36.4) 0.17
*
For white European men, unless otherwise indicated.
†
Proportion of subjects carrying the variant.
‡CHEK2 c.1343T>G (p.Ile448Ser) was the only CHEK2 variant observed in African men and was identified in two cases and no controls of white 
European origin.
§
Based on data from 623 and 569 African-American cases and controls, respectively.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal 
components.
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Table 4
Summary results from the Ovarian Cancer Association Consortium studies for white European women (14 
542 invasive ovarian cancer cases and 23 491 controls)
Variant
Frequency*
Controls
Frequency*
Cases OR (95% CI)
LRT
p Value
PALB2
  c.1592delT (p.Leu531Cysfs) 0.00004 0.00012 2.50 (0.21 to 29.1) 0.45
  c.2816T>G (p.Leu939Trp) 0.00413 0.00399 0.96 (0.69 to 1.34) 0.81
  c.3113G>A (p.Trp1038*) 0.00034 0.00031 1.34 (0.36 to 4.97) 0.66
CHEK2
  c.349A>G (p.Arg117Gly) 0.00038 0.00031 1.07 (0.32 to 3.60) 0.92
  c.538C>T (p.Arg180Cys) 0.00128 0.00160 1.49 (0.83 to 2.67) 0.18
  c.715G>A (p.Glu239Lys) 0.00021 0.00037 1.47 (0.42 to 5.22) 0.54
  c.1036C>T (p.Arg346Cys)‡ 0 0 – –
  c.1312G>T (p.Asp438Tyr) 0.00081 0.00074 0.92 (0.42 to 1.99) 0.83
  c.1343T>G (p.Ile448Ser) 0.00009 0 – –
ATM
  c.7271T>G (p.Val2424Gly) 0 0.00012 – –
*
Proportion of subjects carrying the variant.
‡
c.1036C>T (p.Arg346Cys) was not observed in any sample.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal 
components.
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